Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2091]
News [6483]
Articles [133]
Editorials [5]
Conferences [171]
elearning [10]
Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer
Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )
28 Sep 2019
More ovarian cancer patients benefit from maintenance combined targeted therapy
Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France
More ovarian cancer patients benefit from maintenance combined targeted therapy ( Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France )
28 Sep 2019
Comment: Immunotherapy combination for advanced NSCLC
Dr Marina Garassino - National Tumour Institute, Milan, Italy
Comment: Immunotherapy combination for advanced NSCLC ( Dr Marina Garassino - National Tumour Institute, Milan, Italy )
28 Sep 2019
Comment: Front-line osimertinib significantly lengthens overall survival in...
Dr Marina Garassino - National Tumour Institute, Milan, Italy
Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC ( Dr Marina Garassino - National Tumour Institute, Milan, Italy )
28 Sep 2019
Synthesis, preclinical analysis, and first-inhuman phase I imaging of 89Zr...
Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA
Synthesis, preclinical analysis, and first-inhuman phase I imaging of 89Zr-DFOdaratumumab for CD38 targeted imaging of myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )
25 Sep 2019
PLEIADES: Daratumumab combinations for multiple myeloma
Dr Ajai Chari - Mount Sinai, New York City, USA
PLEIADES: Daratumumab combinations for multiple myeloma ( Dr Ajai Chari - Mount Sinai, New York City, USA )
25 Sep 2019
BCMA: A new biomarker for multiple myeloma
Dr James Berenson - Oncotherapeutics, West Hollywood, USA
BCMA: A new biomarker for multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )
25 Sep 2019
BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed...
Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia
BELLINI: Venetoclax or placebo with bortezomib and dexamethasone for relapsed/refractory multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )
25 Sep 2019
Appraising an NTRK testing algorithm: When, what, how
Professor Jean-Yves Blay and Professor Frédérique Penault-Llorca
Appraising an NTRK testing algorithm: When, what, how ( Professor Jean-Yves Blay and Professor Frédérique Penault-Llorca )
16 Sep 2019
New standard of care for lung cancer patients with EGFR mutations
Dr Gelenis Domingo - Memorial Healthcare System, Hollywood, FL, USA
New standard of care for lung cancer patients with EGFR mutations ( Dr Gelenis Domingo - Memorial Healthcare System, Hollywood, FL, USA )
26 Jul 2019
Evaluating treatment options for acute myeloid leukaemia
Dr Amanda Brahim - Memorial Healthcare System, Hollywood, FL, USA
Evaluating treatment options for acute myeloid leukaemia ( Dr Amanda Brahim - Memorial Healthcare System, Hollywood, FL, USA )
26 Jul 2019
An overview of the latest advances in gastric cancer
Prof Eric Van Cutsem - University of Leuven, Leuven, Belgium
An overview of the latest advances in gastric cancer ( Prof Eric Van Cutsem - University of Leuven, Leuven, Belgium )
17 Jul 2019

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation